A

Anbio Biotechnology

Biotech & Life Sciences · Frankfurt, Germany · Founded 2021 · IPO 2025

Anbio Biotechnology is a global medical device company specializing in in-vitro diagnostics (IVD). Founded in 2015, the company aims to decentralize and personalize diagnostic solutions to enable rapid diagnosis and improve patient outcomes. Anbio offers a range of laboratory, wellness, at-home, and point-of-care testing (POCT) solutions. The company's product portfolio covers various medical fields, including oncology, cardiovascular diseases, infectious diseases, inflammation, hormone analysis, and drugs of abuse testing. It operates with a business model focused on research and development, manufacturing, and global distribution of its diagnostic products. Anbio serves a diverse client base that includes laboratories, healthcare providers, and individuals through its at-home testing kits. The firm generates revenue through the sale of its IVD solutions and devices, emphasizing cost-effectiveness and accessibility for its global customers. In 2021, Anbio was listed as a registered manufacturer for medical devices by the U.S. FDA, and in 2022, it received FDA Emergency Use Authorization (EUA) for its Anbio-AF-100S FIA and its rapid antigen test for COVID-19. Keywords: in-vitro diagnostics, medical devices, point-of-care testing, laboratory diagnostics, rapid tests, oncology diagnostics, cardiovascular testing, infectious disease tests, global medical supplier, FDA approved